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The overexpression of IRX1 gene correlates with the
growth arrest in gastric cancer. Furthermore, overexpres-
sion of IRX1 gene suppresses peritoneal spreading and
long distance metastasis. To explore the precise mechan-
isms, we investigated whether restoring IRX1 expression
affects the angiogenesis or vasculogenic mimicry (VM).
Human umbilical vein endothelial cells (HUVECs) and
chick embryo and SGC-7901 gastric cancer cells were
used for angiogenesis and VM analysis. Small interfering
RNA was used for analyzing the function of BDKRB2,
a downstream target gene of IRX1. As results, the
remarkable suppression on peritoneal spreading and
pulmonary metastasis of SGC-7901 cells by IRX1
transfectant correlates to reduced angiogenesis as well
as VM formation. Using the supernatant from SGC-
7901/IRX1 cells, we found a strong inhibiting effect on
angiogenesis both in vitro and in chick embryo. SGC-
7901/IRX1 cells revealed strong inhibiting effect on VM
formation too. By gene-speciﬁc RNA interference for
BDKRB2, or its effector PAK1, we got an effective
inhibition on tube formation, cell proliferation, cell
migration and invasion in vitro. In conclusion, enforcing
IRX1 expression effectively suppresses peritoneal spread-
ing and pulmonary metastasis via anti-angiogenesis and
anti-VM mechanisms, in addition to previously found cell
growth and invasion. BDKRB2 and its downstream
effector might be potential targets for anti-cancer
strategy.
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Introduction
IRX1 is a newly identiﬁed tumor suppressor gene on
gastric cancer in our previous studies (Lu et al., 2005; Guo
et al., 2010). Meanwhile, the tumor suppressor function of
IRX1 was also conﬁrmed on head and neck squamous cell
carcinoma by others (Bennett et al., 2008, 2009). IRX1
belongs to Iroquois homeobox gene family, which has six
members of IRX1 to IRX6. IRX1 is closely related to
embryonic development, including foregut organs such as
lung (Becker et al., 2001; Alarcon et al., 2008). Our
previous study revealed that restoring IRX1 in gastric
cancer cells arrested cancer proliferation both in vitro and
in vivo. In addition, we found that several downregulated
genes involve in angiogenesis in IRX1-transfected gastric
cancer cells by cDNA microarray analysis (GSE17399).
BDKRB2 is one of the downregulated genes, which
connects to angiogenesis in several tumors (Ishihara
et al., 2002; Wu et al., 2002). Growth of solid tumor relies
on blood vessels to supply oxygen and nutrients. Tumor
progression is accompanied by ﬂourish neovascularization
to satisfy its metabolic demands. Endothelium-dependent
vessels are the predominant microcirculatory mechanism
for solid tumors. Therefore, endothelium is the target of
the anti-angiogenesis treatment (Matsuda et al., 2000;
Getmanova et al., 2006). Vasculogenic mimicry (VM) of
solid tumor is another microcirculatory mechanism, which
is an endothelium-independent pattern. Various types of
malignant tumors demonstrated internal blood supply
network via VM formation, including malignant melano-
ma (Maniotis et al., 1999), inﬂammatory breast cancer
(Shirakawa et al., 2003) prostate cancer (Sharma et al.,
2002), invasive ovarian cancer (Su et al., 2008), sarcoma
(Hao et al., 2002), astrocytoma (Yue and Chen, 2005) and
so on. VM is strongly associated with a poor prognosis in
human tumors. So, VM becomes a potential target for
anti-cancer strategy (Fujimoto et al., 2006; Zhang et al.,
2007; Sun et al., 2008).
Gastric cancer is one of the common solid malignancies
characterized by accumulated genetic and epigenetic
alterations. Peritoneal spreading and metastasis are the
pivotal factors for its poor prognosis. Many efforts have
been made to arrest the peritoneal spreading and long
distance metastasis for gastric cancer. In this paper, we
report a new ﬁnding that enforcing IRX1 expression
disclosed anti-spreading and anti-metastasis efﬁcacies in
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www.nature.com/oncanimal experiments. The biological functions closely
depend on the activity of BDKRB2 gene. BDKRB2
(bradykinin receptor B2, NM-000623.3) is also termed
B2R or BK-2 receptor. This gene encodes a receptor for
bradykinin, which elicits many responses including vaso-
dilation, edema, smooth muscle spasm and pain ﬁber
stimulation. Some study revealed that bradykinin regulates
the secretion and biosynthesis of endothelin-1 through
kinin B2 receptor in melanoma cells (Andoh et al., 2010).
Although BDKRB2 expression has been identiﬁed on
some cancer tissues (Wu et al., 2002), little is known about
its biological functions on gastric carcinoma, especially on
IRX1-related anti-angiogenic mechanism. Our new ﬁnd-
ings will facilitate the understanding of IRX1-mediated
anti-cancer mechanisms on gastric cancer.
Results
Enforcing IRX1 on gastric cancer cells suppresses
peritoneal spreading and lung metastasis in nude mice
A total of 75 nude mice were enrolled in these
experiments. Among them, 30 mice were used for
peritoneal spreading study and 45 for pulmonary
metastatic study. The experimental results were summar-
ized in Table 1. The peritoneal nodules were markedly
suppressed in IRX1 overexpression group, compared
with mock or controls (1.0±0.70 vs 4.4±1.14, Po0.001;
Figure 1a). The tumorigenicity of pulmonary metastasis
was also observed. In IRX1 overexpression group, 2 out
of 15 mice show tumorigenicity in lung, which is
signiﬁcantly lower than that in mock (11/15) and
controls (10/15) (P¼0.002; Figure 1b). Meanwhile, we
assayed the microvessel density by CD34 immunohisto-
chemical stain as well as VM density by periodic acid-
schiff (PAS) histochemical stain. We found a signiﬁcant
reduction of microvessel density and VM density in
tumor tissues of SCG-7901/IRX1 group, compared with
mock or controls (Figure 2).
Enforcing IRX1 on gastric cancer cells suppresses tubular
formation of HUVECs
Human umbilical vein endothelial cells (HUVECs)
(2 10
4cells/well) were suspended in collected super-
natants from SGC-7901, SGC-7901/vector and SCG-
7901/IRX1, respectively. After 18h incubation at 371C
Table 1 Animal experiments for peritoneal spreading and pulmonary metastasis
Animal models Cells lines Cell number Time Tumorigenicity P-value
Peritoneal spreading SGC-7901 2 10
6 4 weeks 4.4±1.14
SGC-7901/vector 2 10
6 4 weeks 4.2±0.83 o0.001
SGC-7901/IRX1 2 10
6 4 weeks 1.0±0.70
Pulmonary metastasis SGC-7901 2 10
6 2 months 11/15
SGC-7901/vector 2 10
6 2 months 10/15 0.002
SGC-7901/IRX1 2 10
6 2 months 2/15
Figure 1 Effect of enforcing IRX1 on peritoneal spreading and metastasis. A 0.1-ml suspension (2 10
6cells/ml) per mouse was
injected into peritoneal cavity or caudal vena. (a) The peritoneal nodules were markedly suppressed in IRX1 overexpression group,
compared with mock or controls (1.0±0.70 vs 4.2±0.83, 4.4±1.14, *Po0.001). (b) Metastatic cancer mass is easily observed
microscopically in mock or controls, compared with experimental animal (the tumor is indicated with arrow, the bar indicates 50mm).
In IRX1 overexpression group, 2 out of 15 mice show tumorigenicity in lung, which is signiﬁcantly lower than that in mock (11/15) and
controls (10/15) (P¼0.002).
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Oncogenewith 5% CO2, tubular numbers of each group were
assessed under light microscope. The supernatant from
SGC-7901/IRX1 revealed strong inhibiting effect on
tubular formation of HUVECs whatever in tubular
number, tubular length and tubular intersecting nods,
compared with mock or control (Figure 3). To examine
the reproducibility of the ﬁnding, we assayed tubular
formation after IRX1 overexpression on NCI-N87
gastric cancer cells. We got a similar result as described
in SGC-7901 cancer cells. The result is presented in
Supplementary Figure 1.
Enforcing IRX1 on gastric cancer cells suppresses VM
Plating 1.5 10
5 cells of SGC-7901, SGC-7901/vector
and SCG-7901/IRX1 on the 3D gel, after 4-day culture
without changing culture media, the cells were ﬁxed with
4% formaldehyde in phosphate-buffered saline (PBS)
for 10min and stained with PAS. The formation of VM
was assessed as PAS-positive extracellular matrix
(ECM) surrounded by cancer cells. SGC-7901/IRX1
cells revealed strong inhibiting effect on VM formation
whatever in tubular length and tubular intersecting
nods, compared with mock or controls (Figure 4).
Enforcing IRX1 on gastric cancer cells suppresses
angiogenesis in chick embryo
A traditional chick embryo chorioallantoic membrane
(CAM) assay was used for observing the effect of
restoring IRX1 on angiogenesis. A 30-ml supernatant
from SGC-7901, SGC-7901/vector and SCG-7901/IRX1
was dropped to the surface of the CAM daily, which
covered a piece of sterilized ﬁlter paper disc. After 3-day
treatment, the eggs were photographed, and the vessel
numbers around the ﬁlter paper disc were assessed. The
blood vessel numbers treated with SCG-7901/IRX1
supernatant were signiﬁcantly reduced, compared with
mock or controls (6.41±2.59 vs 9.18±1.99 and
10.27±2.64, P¼0.001; Figure 5).
Enforcing IRX1 on gastric cancer cells suppresses
cell-ECM adhesive ability
A 150-ml cell suspension of SGC-7901 (1.0 10
6/ml) was
added to the wells coated with ﬁbronectin or collagen IV
and incubated for 60min. After cell staining and
washing, we examined the attached cells in the micro-
titer plate. The OD (optical density) value at 560nm
represents the cell-ECM adhesive ability. The OD 560
value of SGC-7901/IRX1 cells was signiﬁcant lower
than that in mock or controls on type IV collagen
assay (0.576±0.043 vs 0.653±0.059, 0.717±0.061,
P¼0.002). The OD 560 value of SGC-7901/IRX1 cells
was signiﬁcant lower than that in mock or controls on
ﬁbronectin assays too (0.682±0.040 vs 0.813±0.005,
0.870±0.040, Po0.001).
IRX1 can downregulate BDKRB2 or its downstream
effector PAK and inﬂuence multiple biological behaviors
Our previous cDNA microarray and chromatin im-
munoprecipitation implied that BDKRB2 functions as
one of downstream targets of IRX1 transcription factor.
We transfected IRX1 to SGC-7901 cancer cells and
found that BDKRB2 expressing level was signiﬁcantly
decreased by RT–PCR and western blot (Figure 6a).
We knocked down BDKRB2 by gene-speciﬁc small
Figure 2 Assays of microvessel density (MVD) or vasculogenic mimicry density (VMD) on tumor tissues. (a) MVD of tumor tissues
was assayed by CD34 immunohistochemistry. A signiﬁcant reduction of MVD in tumor tissues of SCG-7901/IRX1 group, compared
with mock or controls (3.8±0.83 vs 7.4±1.51 or 6.8±1.30, *Po0.001, the bar indicates 20mm) .( b) VMD of tumor tissues was
assayed by PAS histochemistry. A signiﬁcant reduction of VMD in tumor tissues of SCG-7901/IRX1 group, compared with mock
or controls (1.20±1.30 vs 4.4±1.14 or 4.4±1.34, *P¼0.002, the bar indicates 20mm).
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Oncogeneinterfering RNA (siRNA) in SGC-7901 cancer cells,
and observed the efﬁcacy on angiogenesis by endothelial
tube formation assay. After 48h siRNA interference,
a signiﬁcant reduction of endothelial tube formation
was identiﬁed in BDKRB2-siRNA group (11.75±2.36),
compared with mock (17.75±1.25) or controls
(19.75±2.22), by calculation of the tubular numbers
(P¼0.001; Figure 6b). We introduced siRNA-speciﬁc
targeting IRX1 to SGC-7901 cancer cells and found
that knockdown of IRX1 in gastric cells reversed the
Figure 3 Effect of enforcing IRX1 on tubular formation in vitro. The supernatants from cells with or without IRX1 transfection were
collected. After 18h co-cultivation with HUVECs, tubular formation was evaluated. (a) Poorly formed tubular structure was observed
in SCG-7901/IRX1 group, compared with mock or controls. (b) The bar charts represent the counting of tubules number (left,
*Po0.001), tubular length (middle, *P¼0.022) and intersecting nods (right, *Po0.001) between different groups. The data represent
the mean±s.d. of three independent experiments.
Figure 4 Effect of enforcing IRX1 on vasculogenic mimicry in vitro. Tumor cells of 1.5 10
5 with or without IRX1 transfection were
plated onto the 3D gel plate. After 4-day culture, the cells were stained with PAS reagent. (a) Microscopically, less tubular structures
with PAS stain were observed in IRX1 transfectant, compared with mock or controls (the bar indicates 20mm). (b) IRX1 transfectants
revealed strong inhibiting effect on tubular length of vasculogenic mimicry (top, 239.52mm±6.32 vs 419.77mm±48.90 or
448.79mm±22.30, *Po0.001) and tubular intersecting nods (down, 6.6±1.14 vs 16±2.0 or 14.4±1.14, *Po0.001). Each experiment
was performed at least three times.
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Oncogeneexpression of BDKRB2 signiﬁcantly (Figure 6c). Mean-
while, we assayed the protein expression of BDKRB2
and IRX1 on peritoneal tumor tissues from nude mice
by immunohistochemical stain. We found a signiﬁcant
reduction of BDKRB2 expression in tumor tissues at
IRX1 overexpressing group, compared with control
(Figure 6d). In wound healing assay, overexpression of
IRX1 alone suppressed the cell migration signiﬁcantly
(Figure 6e, lane 2) and overexpression of BDKRB2
alone signiﬁcantly enhanced the cell migration
(Figure 6e, lane 3). Co-expression of BDKRB2 and
IRX1 revealed the effect observed as in control
(Figure 6e, lane 4). The similar effects on cell migration
and invasion were also observed by transwell assay
(Figure 6f), along with the cell viability examination.
The cell viability in SGC-7901, SCG-7901/IRX1, SGC-
7901/BDKRB2 and SGC-7901/IRX1/BDKRB2 at in-
itial point was 97.475±0.502, 97.235±0.728, 96.08±
0.438 and 96.065±0.120, respectively (P¼0.09). The
cell viability of above different groups in 24h point
was 93.765±0.771, 91.88±3.295, 93.595±0.813 and
92.15±1.753, respectively (P¼0.71), and in 48h point
was 84.465±0.134, 81.655±1.746, 83.515±1.972 and
82.75±0.296, respectively (P¼0.32). To examine the
reproducibility of the ﬁnding, we compared the wound
healing ability after BDKRB2 and IRX1 overexpression
on NCI-N87 gastric cancer cells. We got the similar
result as described in SGC-7901 cancer cells. The result
is presented in Supplementary Figure 1.
By KEGG pathway analysis, p21-activated kinase
(PAK) is identiﬁed as a key effector in bradykinin
pathway. To validate the association of IRX1 and
BDKRB2 pathway, we transfected IRX1, siRNA-PAK1
or both IRX1 and siRNA-PAK1 to SGC-7901 cells,
respectively. We found that overexpression of IRX1
downregulated PAK1 expressing level, whereas knock-
down of PAK1 level did not alter the IRX1 level
signiﬁcantly (Figure 7a). We examined the cell prolifer-
ating activity after IRX1 overexpression or interfering
PAK1 by siRNA. We found that the cell proliferation
was obviously downregulated in IRX1 overexpressing
group or PAK1 interfering group, compared with
controls. Whereas the cell proliferation activity in
7901/IRX1/siRNA-PAK1 group was nearly the same
as that observed in IRX1-overexpressed cells
(Figure 7b). By transwell assays, overexpression of
IRX1 or knockdown of PAK1 downregulated the
transferred cell numbers. Whereas, in 7901/IRX1/
siRNA-PAK1 group, the transferred cell numbers did
not change so much relative to IRX1-overexpressed cells
(Figure 7c). These ﬁndings suggested that IRX1 gene can
regulate downstream BDKRB2-PAK1 levels as well as
their associated functions.
Discussion
Tumors require a blood supply for growth and
hematogenous dissemination. Much attention has been
focused on the role of angiogenesis, a recruitment of
new vessels from pre-existing vessels. However, angio-
genesis may not be the only mechanism by which tumors
acquire a microcirculation. Highly aggressive tumors are
capable of forming highly patterned VM that is
composed of a basement membrane that stains positive
with the PAS histochemical reagent in the absence
of endothelial cells and ﬁbroblasts. IRX1 is a newly
identiﬁed tumor suppressor gene. Hitherto, the tumor
suppressor function of IRX1 transcription factor has
been reported by us as well as by Bennett and colleagues
Figure 5 Effect of enforcing IRX1 on angiogenesis in chick embryo CAM. (a) Schematic feature of how to open a window on
fertilized chicken egg. (b) Dissecting microscope graphs of chick embryos. A remarkable reduction of blood vessels was observed in
IRX1 transfectant, compared with mock or controls. (c) The bar chart of vessel numbers around ﬁlter. The blood vessel numbers in
SCG-7901/IRX1 (6.41±2.59) group were signiﬁcantly reduced, compared with mock (9.18±1.99) or control (10.27±2.64, *Po0.001).
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OncogeneFigure 6 Analyzing the association between BDKRB2 with IRX1 and biological functions. (a) By chromatin immunoprecipitation,
BDKRB2, a downstream target gene of IRX1 is identiﬁed (left). The mRNA (middle, *Po0.001) and protein levels (right) of BDKRB2
were signiﬁcantly decreased by IRX1 overexpression. (b) After 48h treatment by siRNA-BDKRB2, a signiﬁcant reduction of
endothelial tube formation was identiﬁed, compared with mock or controls by counting the tubular number (11.75±2.36 vs
17.75±1.25 or 19.75±2.21, *Po0.001). The data represent the mean±s.d. of three independent experiments. (c) Overexpression of
IRX1 downregulated BDKRB2 expression. Whereas knocking down IRX1 by siRNA on IRX1-overexpressed cells can reverse the
expressing level of BDKRB2. (d) Immunohistochemical staining for BDKRB2 and IRX1 on peritoneal tumor tissues of nude mice.
A signiﬁcant reduction of BDKRB2 expression in tumor tissue was observed at IRX1 overexpressing group, compared with control
(the bar represents 20mm). (e) In wound healing assay, overexpression of IRX1 alone suppressed the wound healing signiﬁcantly (lane 2)
and overexpression of BDKRB2 alone enhanced wound healing signiﬁcantly (lane 3). Co-expression of BDKRB2 and IRX1 revealed
the effect observed as control (lane 4). The mean wound distances of 7901/IRX1, 7901/BDKRB2 and 7901/IRX1/BDKRB2 were
322.88±22.45, 53.67±4.16 and 80.33±3.06, respectively, at 48h (Po0.001). (f) The similar effects on cell migration and invasion were
also observed by transwell assay. The amount of migrated cells in 7901/IRX1, 7901/siRNA-BDKRB2 and 7901/IRX1/BDKRB2 was
31±4.00 vs 165±8.54 and 123±3.05, respectively (Po0.001). The amount of invasive cells in 7901/IRX1, 7901/BDKRB2 and 7901/
IRX1/BDKRB2 was 28.67±4.04 vs 168.33±3.06 and 134.33±2.52, respectively (Po0.001). The data represent the mean±s.d. of three
independent experiments.
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Oncogene(Lu et al., 2005; Bennett et al., 2008, 2009; Guo et al.,
2010). However, the detailed biological functions of
restoring IRX1 expression on gastric cancer remain to
be explored. In the present study, we further demon-
strate that peritoneal spreading and long distance
metastasis were arrested by restoring IRX1 expression
on gastric cancer cells. These functions are mediated by
interference of angiogenesis and VM formation both
in vitro and in vivo. On previous microarray analysis, we
found out BDKRB2, a downregulated gene, which
involves in the regulation of blood vessels. Along with
the important clue, we explored the association between
IRX1 expression and angiogenesis, VM and ECM
adhesive capacity.
Rich blood supply is the basis of tumor growth,
spreading and metastasis. Tube formation assay is based
on the ability of endothelial cells to form 3D capillary-
like structures when cultured on a gel of basement
membrane extract (Masamune et al., 2008; Nogueras
et al., 2008). VM is a newly identiﬁed phenomenon
different from traditional tumor angiogenesis. VM was
ﬁrst described as the ﬂuid-conducting channels formed
in highly aggressive melanoma cells by Maniotis et al.
(1999). The channels of VM are lack of endothelial cells
of liner with abundance of PAS-positive substances in
the ECM. Either red blood cells or plasma could appear
in those channels (Sood et al., 2001; Sun et al., 2004,
2006; van der Schaft et al., 2005). Importantly, one
report suggested that SGC-7901 gastric cancer cells can
form VM in 3D culture (Zhang, 2008). Our experiments
conﬁrmed that overexpression of IRX1 on SGC-7901
cells effectively inhibited the formation of capillary and
VM structures. In chick CAM assay, another in vivo
model for studying the angiogenic activity (Deryugina
and Quigley, 2008a,b), we further conﬁrmed that
overexpression of IRX1 signiﬁcantly inhibited angio-
genesis on avian embryo.
Another factor that inﬂuences the process of tumor
spreading and metastasis is tumor-ECM adhesive
ability. During the process of metastasis, tumor cells
leave the primary site, travel via blood and/or lymphatic
circulatory systems, attach to the substratum of ECM at
a distant site, and establish a secondary tumor,
accompanied by angiogenesis of the newly formed
neoplasm (Gupta and Massague, 2006; Lorch et al.,
2007; Veeravalli et al., 2010). Therefore, examination of
adhesive ability of tumor cells to ECM will become an
important indicator for invasiveness. Our experiments
Figure 7 Observing the effect of interfering PAK1, an effector of BDKRB2 in IRX1-overexpressed cancer cells. (a) Overexpression of
IRX1 downregulated PAK1 expressing level, whereas knockdown of PAK1 level did not alter the IRX1 level signiﬁcantly.
Overexpression of IRX1 combined with siRNA-PAK1 also downregulated PAK1 expressing level signiﬁcantly by western blot. (b) The
cell proliferation activity was suppressed signiﬁcantly in 7901/IRX1 or 7901/siRNA-PAK1 groups, compared with controls
(*Po0.001). The cell proliferation activity in 7901/IRX1/siRNA-PAK1 co-transfected group was nearly the same as that observed in
7901/IRX1 alone group (P¼0.061). (c) By transwell assays, the migrated cell numbers (top) were signiﬁcantly reduced in 7901/IRX1
group (77.33±4.25) or 7901/siRNA-PAK1 group (84±1), compared with control (206.66±8.5, *Po0.001). Whereas in 7901/IRX1/
siRNA-PAK1 co-transfected group, the migrated cell numbers were nearly the same as that observed in 7901/IRX1 alone group
(70.66±1.52 vs 77.33±4.25, P¼0.202). The invasive cell numbers (down) were signiﬁcantly decreased in 7901/IRX1 group
(79.66±5.03) or 7901/siRNA-PAK1 group (71±6), compared with control (178±4.58, *Po0.001). Whereas in 7901/IRX1/siRNA-
PAK1 co-transfected group, the invasive cell numbers were nearly the same as that observed in 7901/siRNA-PAK1 alone group
69±5.57 vs 71±6, *P¼0.113). The data represent the mean±s.d. of three independent experiments.
IRX1 inﬂuences peritoneal spreading and metastasis
J Jiang et al
4504
Oncogenedemonstrated that IRX1 overexpression weakened the
adhesive ability of cell-collagen IV and cell-ﬁbronectin
adhesion.
As to blood supply of tumor, much study focused on
the ‘classic’ genes, such as vascular endothelial growth
factor (Altundag et al., 2004). In our studies, vascular
endothelial growth factor or other metastasis-associated
factor matrix metalloproteinases were not changed so
much after IRX1 overexpression (Supplementary Figure
1). We found that BDKRB2 and its effector PAK1 are
downregulated by IRX1 overexpression. BDKRB2 is a
9 amino acids bradykinin peptide receptor, which is
constitutively expressed in vasculature. Bradykinin
functions as a positive regulator for angiogenesis.
BDKRB2 is overexpressed in various types of human
cancer (Ishihara et al., 2002; Krankel et al., 2008).
In addition, BDKRB2 interacts with integrin a5 b1t o
transactivate epidermal growth factor receptor in kidney
cells (Kramarenko et al., 2010). Ikeda et al. (2004)
found that antagonizing bradykinin can reduce angio-
genesis and tumor growth in rats. BDKRB2 knockout
mice showed decreased growth of tumor xenografts due
to inhibited angiogenesis. BDKRB2 mediated induction
of cyclooxygenase-2 and endothelin-1, which function as
stimulators of vascular formation (Basu et al., 2006;
Zhang et al., 2008; Andoh et al., 2010). We evaluated the
roles of BDKRB2 in tumor-associated angiogenesis on
cell model. RNA interference (RNAi) is a process in
which double-strand RNA directs the speciﬁc degrada-
tion of a corresponding target mRNA. The mediators of
this process are small double-strand RNAs, of B21bp
in length, called siRNAs (Calderon and Lavergne, 2005;
Oleinikov et al., 2005; Bessard et al., 2008). siRNAs can
be transfected into cells and direct the degradation of
corresponding mRNAs. Hence, siRNAs represent a
powerful tool for studying gene functions, as well as
having the potential of being highly speciﬁc pharma-
ceutical agents (Gartel and Kandel, 2006; Gu et al.,
2008). PAK, a mammalian homologs of Ser/Thr
protein kinase, is the effector of bradykinin peptide
receptors pathway, which has been implicated in a
variety of intracellular signaling events, including cell
cytoskeleton rearrangement, proliferation, cell-cycle
progression, cell migration and angiogenesis (Tang
et al., 2000; Fryer and Field, 2005; Galan Moya et al.,
2009). Overexpression and activation of PAK has been
identiﬁed in the development of cancers (Kumar and
Vadlamudi, 2002; Liu et al., 2009). Recently, targeting
PAKs have been proposed as a potential therapeutic
strategy for gastric cancer (Cai et al., 2009; Li et al.,
2010). In this study, protein levels of BDKRB2 and its
downstream effector PAK1 were obviously downregu-
lated by overexpression of IRX1 gene in gastric cancer
cells. We knocked down the BDKRB2 or PAK1 by
RNAi and got an obvious inhibitory effect on tube
formation, cell proliferation, cell migration and inva-
sion. Our results suggested that BDKRB2 promote
tumor proliferation and invasion by increased blood
supply combined with other survival signals. Because
BDKRB2 antagonist has been developed (Ishihara
et al., 2002), the administration of BDKRB2 antagonist
may provide a promising method for anti-cancer
therapy.
In conclusion, our data, for the ﬁrst time, implicate
that IRX1 suppresses peritoneal spreading and long
distance metastasis via inhibiting BDKRB2-dependent
angiogenesis and VM mechanisms on gastric cancer.
When we inhibited BDKRB2 by speciﬁc RNAi, a
remarkable reduction of neovascularization was ob-
served. BDKRB2 might be a potential target for anti-
cancer strategy.
Materials and methods
Cell culture and transfection of IRX1 gene
Human gastric cancer cell SGC-7901 and HUVECs were
preserved in our institute. Brieﬂy, cells were grown in
RPMI1640 supplemented with 10% fetal calf serum, and
2mmol L-glutamine. Cells were maintained at 371C with 5%
CO2. pEGFP-N1-IRX1 eukaryotic expression vector was
constructed as previously described (Guo et al., 2010).
pReceiver-M03-BDKRB2 eukaryotic expression vector was
purchased from FulenGen Company (Guangzhou, China).
Transfectant of the empty vectors was used as controls. After
48h incubation of SGC-7901 with transfectants, the super-
natants were collected for further studies.
Endothelial tube formation assay
Angiogenesis in vitro was assessed by the endothelial tube
formation assay kit (Cell Biolabs, San Diego, CA, USA). The
tube formation assay is based on the ability of endothelial cells
to form 3D capillary-like tubular structures when cultured on
a gel of basement membrane extract. Brieﬂy, each well of
prechilled 96-well culture plates was coated with a thin layer of
the ECM gel prepared from Engelbreth-Holm-Swarm tumor
cells (50ml/well), which was left to polymerize at 371C for 1h.
HUVECs were resuspended in collected supernatants from
controls (SGC-7901), mock (SGC-7901/vector), SCG-7901/
IRX1, SGC-7901/siRNA-BDKRB2, respectively. HUVECs
(2 10
4cells/well) were added to the polymerized ECM gel
with 300ml of the supernatants. After 18h incubation at 371C
with 5% CO2, the tube formation ability was evaluated by
counting the tubular number, the tubular length and tubular
intersecting nods in ﬁve random ﬁelds using Image Pro Plus
software (Media Cybernetics Inc., Bethesda, MD, USA; Serial
No. 45N51000-33993) according to Mirshahi’s method (Mirshahi
et al., 2009). Each experiment was performed at least three times.
VM assay on 3D culture
3D type I collagen gel and matrigel mixture were produced as
following: 25ml of type I collagen (BD Bioscience, Bedford,
MA, USA; 3.7mg/ml) and matrigel (BD Bioscience) were
mixed according to 1:1, dropped onto 16mm glass cover slides
in six-well culture plate. Absolute ethanol of 100ml was
added to each well until the gel was polymerized at room
temperature. After a wash with PBS, 1.5 10
5 cells of SGC-
7901, SGC-7901/vector and SCG-7901/IRX1 were plated onto
the gel plate. After 4-day culture without changing culture
media, the cells were ﬁxed with 4% formaldehyde in PBS for
10min, then stained with PAS stain and counterstained with
hematoxylin. The vascular mimicry formation ability was
evaluated by counting the average vascular mimicry length and
intersecting nods. Each experiment was performed at least
three times.
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Adhesion of tumor cells to ECM is a pivotal step in developing
tumor dissemination. The CytoSelect 48-well cell adhesion kits
(ﬁbronectin-coated and collagen IV-coated; Cell Biolabs, Inc.,
San Diego, CA, USA) were used in this experiment. The
microtiter plates were warmed up at room temperature for
10min. The RPMI1640 was prepared according to instruction
contained 0.5% bovine serum albumin, 2mM CaCl2 and 2mM
MgCl2, and used to resuspend the cells of SGC-7901, SGC-
7901/vector and SGC-7901/IRX1. A 150mlo f1  10
6cells/ml
suspension was added to each well and incubated for 60min.
Non-speciﬁc protein binding of the coated wells was blocked
by adding 1% (w/v) bovine serum albumin (41C, 12h) and
rinsing the wells with Hepes buffer. Non-adherent cells were
removed by washing three times with PBS. A 200-ml cell stain
solution was added to each well and retained for 10min at
room temperature, discarding stain solution and washing three
times with PBS. The total adhesive cells were determined by
dissolving the attached cells in the microtiter wells with 200ml
cell extraction solution. The absorbance of each well was
measured at 560nm with microtiter plate reader (TD-20/20
analytical luminometer, Sunnyvale, CA, USA). OD showed a
linear relationship to the amount of cells and was corrected for
dying of bovine serum albumin/polystyrene without cells.
Chick embryo CAM assay
Fertilized chicken eggs (Xing-Huo farm, Shanghai, China)
were incubated at 371C with humidity of 70%. On the 6th day
of incubation, a round window was opened on the shell.
Normally developed embryos were used for experiment.
Malformated or dead embryos were excluded from experi-
ment. The open window was sealed with transparent tape
and incubated overnight. On the 7th day, a piece of sterilized
ﬁlter paper disc (0.5cm diameter) was placed on the surface
of the CAM. A 30-ml collected supernatant from SGC-7901,
SGC-7901/vector and SCG-7901/IRX1 was dropped to ﬁlter
paper disc daily and sealed with transparent tape for
consecutive 3 days. On the 10th day of incubation, the eggs
were photographed with MacroPATH dissecting microscope
(Milestone, Italy). The vessel numbers around the ﬁlter paper
disc were assessed. All vessels vertically to the disc or
intersected with the disc at an angle greater than 451 were
counted.
Nude mice study
In this experiment, both peritoneal spreading and pulmonary
metastasis were observed. Four-week-old male BALB/C nude
mice were purchased from the Institute of Zoology, Chinese
Academy of Sciences of Shanghai. All experiments were
performed in accordance with the ofﬁcial recommendations
of the Chinese animal community. In peritoneal spreading
study, 10 mice were enrolled in each group. In all, 2 10
7cells/
ml of SGC-7901, SGC-7901/vector and SCG-7901/IRX1 were
resuspended. A 0.1-ml suspension per mouse was injected
intraperitoneally. In pulmonary metastasis study, 15 mice were
enrolled in each group. In all, 2 10
7cells/ml of SGC-7901,
SGC-7901/vector and SCG-7901/IRX1 were resuspended.
A 0.1-ml suspension per mouse was injected into caudal vena.
On the 30th day after intraperitoneal injection, mice were
killed by cervical decapitation. The abdominal masses were
excised and ﬁxed with 10% buffered formalin for further
morphological analysis. On the 60th day after caudal vena
injection, mice were killed by cervical decapitation. The
thoracic cavity of mice was examined carefully. The pulmo-
nary metastatic masses were removed and ﬁxed with 10%
buffered formalin for further morphological analysis.
Histochemistry and immunohistochemistry
All parafﬁn-embedded specimens were cut into serial 5mm sections.
The sections were deparafﬁnized, rehydrated and subjected to
histochemical and immunohistochemical staining. The immuno-
histochemistry was conducted with monoclonal rat anti-mouse
CD34 (1:50 dilution; Abcam, Cambridge, MA, USA), mouse
anti-human BDKRB2 (1:50 dilution; Abcam), rabbit anti-human
IRX1 (1:50 dilution; Bioworld, Louis Park, MN, USA). Dako
two-step detection Kit was used (Dako, Carpinteria, CA, USA).
The histochemistry was performed with PAS staining. The slides
were counterstained with hematoxylin and viewed with light
microscope. Microvessel density and vascular mimicry density
per mm
2 were calculated, respectively, in ﬁve random ﬁelds.
Chromatin immunoprecipitation
Chromatin immunoprecipitation assays were performed accord-
ing to the kit manual (Upstate, Billerica, MA, USA). SGC-7901
cells were cultured in 1640 culture medium with 10% fetal
serum, till the density of 90%, and then collected and subjected
to sodium dodecyl sulfate lysation after formaldehyde cross-
link of DNA and proteins at room temperature for 10min.
After sonication, antibodies of normal mouse IgG and speciﬁc
antibodies to IRX1 (Abcam) were added and mixed overnight
with rotation. After adding the protein G agrose to collect the
antibody/antigen/DNA complex, the complex then undergo
washing and elution, and reverse crosslinked by 5 M NaCl treat-
ment in 651C for 5h. Puriﬁed chromatins were then analyzed
by PCR with speciﬁc primers for BDKRB2 gene, along with
control primers to detect GAPDH gene.
RNAi experiments
To verify the association of candidate genes with the biological
functions, RNAi technology was used. SGC-7901 cells (3 10
5
cells) were plated onto six-well plates until 50% conﬂuence.
The cells were transfected with siRNA (GenePharma Co.,
Shanghai, China) targeting BDKRB2, IRX1 and PAK1 in
accordance with the manufacturer’s instructions (the sequences
of siRNAs were listed in Supplementary Table). Brieﬂy, a 10-ml
transfection reagent was incubated with 500ml OPTI-MEM
medium (Gibco, Carlsbad, CA, USA) for 5min. Subsequently,
siRNAs were added to wells (120nmol/l). After 2 days trans-
fection, cells were collected for protein expressing analysis.
Invasion, migration and cell viability assays
Cell invasion and cell migration assay were performed. The
transwell chamber was used (8mm, 24-well format; Corning,
Lowell, MA, USA). In invasion assay, the insert membranes
were coated with diluted Matrigel (BD Biosciences). Cells
(1 10
5) were added to upper chamber and cultured for 48h.
In migration assay, the insert membranes were not coated with
Matrigel and cultured in the same condition. Finally, the insert
membranes were cut and stained with Crystal violet (0.04% in
water; 100ml) and counted the permeating cells under the
inverted microscope and photographed. Meanwhile, the cell
viability (1 10
5) of different groups with same culture
conditions was also assayed at 0, 24 and 48h time points by
cell counter (Coulter, Sequim, WA, USA). At least three
independent experiments were performed for all conditions.
The data are shown as means±s.d.
Protein analysis
Protein lysates were prepared from collected cells in lysis
buffer containing 20mM/l Hepes, 0.15 M NaCl and 1%
Triton X-100 supplemented with 80ml/ml phosphatase inhi-
bitor cocktail II (Sigma, St Louis, MO, USA) and 10ml/ml
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GmbH, Indianapolis, IN, USA). Protein was quantiﬁed by
Bio-Rad protein assay kit (Bio-Rad, Hercules, CA, USA), with
bovine serum albumin as control. Protein (100mg) was
separated by 8% sodium dodecyl sulfate polyacrylamide gel
electrophoresis. Membrane was detected by BDKRB2, IRX1
and PAK1 antibodies. GAPDH antibody was used for internal
control (Supplementary Table).
Statistics
Data are shown as mean±s.d. The statistical difference
between the two groups was examined by Student’s t-test.
Multiple comparisons were performed by one-way analysis of
variance. Po0.05 was considered statistically signiﬁcant.
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